vascular endothelial growth factor

(redirected from Pazopanib)
Also found in: Dictionary, Medical.

vascular endothelial growth factor

[¦vas·kyə·lər ‚en·dō¦thē·lē·əl ′grōth ‚fak·tər]
(medicine)
A soluble factor that acts through specific cell-surface receptors on endothelial cells to critically regulate vasculogenesis.
References in periodicals archive ?
NCCN is pleased to announce that we will be funding five new ofatumumab research studies and seven pazopanib research studies in 2011, in addition to more than 50 active clinical and correlative trials that we are already supporting," commented Diane Paul, MS, RN, Vice President, ORP, NCCN.
The award was one of seven grants for clinical trials with pazopanib that were supported through the NCCN Clinical Trials Network (CTN).
The drug pazopanib may help revolutionize the care of patients with metastatic, rapidly progressive differentiated thyroid cancers, say researchers at Mayo Clinic who are publishing findings of a phase II clinical trial in The Lancet Oncology.
The National Comprehensive Cancer Network (NCCN) has been awarded two individual $2 million grants from GlaxoSmithKline (GSK) to support clinical studies of ofatumumab (Arzerra([R]), GlaxoSmithKline) in the treatment of hematologic malignancies and pazopanib (Votrient([R]), GlaxoSmithKline) in the treatment of solid tumors.
or purchases) dabrafenib, Nilotinib, Everolimus, Lapatinib, Pazopanib, Basiliximab, Mycophenolic acid, Verteporfin and octreotide.
2) He started pazopanib 400 mg daily titrated up to 600 mg daily two weeks later.
However, it would not be useful to have data on tivozanib without being able to compare it with pazopanib and sunitinib, and it is not currently possible to collect the information for pazopanib and sunitinib through the Cancer Drugs Fund.
Drugs such as CMB-305, efatutazone, everolimus, HDM-201, interferon gamma-1b, KM-3174, palbociclib, pazopanib hydrochloride, pembrolizumab, ribociclib succinate, and selinexor are studied in the report.
15) Other tyrosine kinase inhibitors that are used following the development of resistance (but that are not currently FDA approved for this indication) include sorafenib (Nexavar, Bayer), nilotinib (Tasigna, Novartis), dasatinib (Sprycel, Bristol-Myers Squibb, Princeton, New Jersey), and pazopanib (Votrient, GlaxoSmithKline, Brentford, United Kingdom).
A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis," Cell Death & Disease, vol.
The target therapy, Pazopanib 400 mg per day, was given for palliative treatment due to suspect disease progression.
Supuran, Polypharmacology of sulfonamides: pazopanib, a multitargeted receptortyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases, Chem.